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Edited by Beat ImhofAbstract Nepmucin/CLM-9 is an Ig domain-containing sia-
lomucin expressed in vascular endothelial cells. Here we show
that, like CD31, nepmucin was localized to interendothelial con-
tacts and to vesicle-like structures along the cell border and
underwent intracellular recycling. Functional analyses showed
that nepmucin mediated homotypic and heterotypic cell adhe-
sion via its Ig domain. Nepmucin-expressing endothelial cells
showed enhanced lymphocyte transendothelial migration
(TEM), which was abrogated by anti-nepmucin mAbs that block
either homophilic or heterophilic binding. Notably, the mAbs
that inhibited homophilic binding blocked TEM without aﬀect-
ing lymphocyte adhesion. These results suggest that endothelial
nepmucin promotes lymphocyte TEM using multiple adhesion
pathways.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The transendothelial migration (TEM) of leukocytes is a
crucial step during inﬂammation and immune surveillance.
In response to inﬂammatory stimuli, various types of leuko-
cytes enter the local sites of infection or injury by transmigrat-
ing through transiently activated postcapillary venules [1].
During immune surveillance, lymphocytes constitutively trans-Abbreviations: LNs, lymph nodes; HEVs, high endothelial venules;
PPs, Peyers patches; LBRC, lateral border recycling compartment;
MBEC4, mouse brain endothelial cell 4; EC, endothelial cell; TEM,
transendothelial migration
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doi:10.1016/j.febslet.2008.07.041migrate into the secondary lymphoid organs, such as lymph
nodes (LNs) and Peyers patches (PPs), through high endothe-
lial venules (HEVs) [2].
A number of adhesion molecules expressed in the intercellu-
lar junction of endothelial cells (ECs) are involved in leukocyte
TEM; they include CD31/PECAM-1 [3], CD99 [4], JAM-A/
-B/-C [5], ESAM [6], and ALCAM [7]. During TEM, the
endothelium appears to employ diﬀerent molecules for
diﬀerent types of leukocytes. Blockade of CD31 strongly inhib-
its neutrophil and monocyte TEM [3]; CD99 promotes
monocyte [4] and neutrophil [8] TEM in vitro and lymphocyte
migration into inﬂamed tissues in vivo [9]; JAM-A facili-
tates TEM of monocytes, neutrophils, and memory T cells
[10,11]; JAM-C regulates monocyte [12] and neutrophil
[13] TEM in vivo. JAM-C also promotes lymphocyte TEM
in vitro [14]. However, the adhesion molecules regulating the
TEM of naı¨ve lymphocytes in vivo remain to be fully charac-
terized.
Recent ﬁndings have shed light on the mechanism of leuko-
cyte TEM. CD31 is concentrated in a vesicle-like compartment
connected to the cell surface, termed the lateral border recy-
cling compartment (LBRC); CD31 in this compartment is con-
stitutively recycled along the lateral border [15,16]. When
monocytes transmigrate, recycling CD31 in the LBRC is tar-
geted directly to the zone of the endothelial cell (EC) border
where transmigration is occurring, which apparently facilitates
TEM [15,16].
Recently we identiﬁed a novel Ig domain-containing sia-
lomucin, nepmucin, expressed in the vascular ECs of various
tissues including those of HEVs in LNs but not in PPs [17].
Nepmucin is part of a multigene family on mouse chromo-
some 11 and is identical to CLM-9 [18]. LN HEV-associated
nepmucin supports L-selectin-dependent lymphocyte rolling
through its mucin-like domain and mediates lymphocyte
binding through its Ig domain [17]. The nepmucin-mediated
lymphocyte binding is apparently heterophilic because nep-
mucin is not expressed on circulating lymphocytes. Here, we
addressed whether nepmucin also participates in lymphocyte
TEM.blished by Elsevier B.V. All rights reserved.
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2.1. Animals
C57BL/6 mice were purchased from Japan SLC. The experimental
protocol was approved by the Ethics Review Committee for Animal
Experimentation of Osaka University Medical School.2.2. Establishment of ECs expressing nepmucin
To prepare the mouse nepmucin expression constructs, cDNAs
encoding full-length nepmucin (FL-nepmucin), nepmucin lacking the
mucin-like domain (Dmucin-nepmucin), and nepmucin lacking the Ig
domain (DIg-nepmucin) were inserted into a mammalian expression
vector, pEF-BOS (bsr). The MBEC4 (mouse brain endothelial cell
4), mouse brain endothelial cell [19], was transfected with the nepmucin
expression constructs (FL-MBEC4, Dmucin-MBEC4, or DIg-MBEC4)
or vector alone (Mock-MBEC4) using Lipofectamine LTX (Invitro-
gen). MBEC4 cells expressing nepmucin stably were selected by the
addition of 5 lg/ml of blasticidin (Invitrogen) and enriched by auto-
MACS (Miltenyi Biotec).A B C
2.3. Reagents
Anti-CD31 mAb (clone 390) and biotinylated anti-CD31 mAb
(MEC13.3) were from BD Pharmingen. Anti-VCAM-1 mAb (clone
429) was from eBioscience. Anti-JAM-A mAb (H202.106) [20] was
kindly provided by Dr. Beat A. Imhof (Centre Medical Universitaire,
Geneva, Switzerland). Anti-nepmucin mAbs (ZAQ1–ZAQ5) and nep-
mucin–human Ig chimeras (nepmucin-Fc) were prepared as described
previously [17].E FD
2.4. Immunoﬂuorescence and immunoelectron microscopy
Immunoﬂuorescence and immunoelectron microscopy of LN sec-
tions were performed as described previously [17,21]. Immunoﬂuores-
cent labeling of FL-MBEC4 using anti-nepmucin and anti-JAM-A
antibodies was described previously [22].2.5. Membrane recycling experiments
A recycling pool of adhesion molecules was selectively labeled as de-
scribed previously [15]. In brief, EC monolayers were incubated with
rat mAbs against mouse nepmucin (ZAQ5), JAM-A, or VCAM-1
for 1 h at 37 C, washed, and then incubated with goat anti-rat IgG
at 4 C, to block mAbs bound to adhesion molecules remaining on
the cell surface. After being washed, the ECs were incubated with
Alexa Fluor 488-conjugated goat anti-rat IgG at 37 C for the indi-
cated periods, to detect molecules that reappeared on the cell surface
after being internalized. G
2.6. Cell aggregation assay
Cell aggregation was assayed as described [23]. The aggregation in-
dex was calculated as D = (N0  Nt)/N0, where N0 is the initial number
of particles corresponding to the total number of cells, and Nt is the
number of remaining particles at the incubation time point t.H2.7. Transendothelial migration assay
EC monolayers on polycarbonate ﬁlter inserts (8-lm pores) were
incubated with IL-1b (50 pg/ml) for 6 h [8], and then plastic non-adher-
ent spleen cells (18.6% CD4+ cells, 12.7% of CD8+ cells, and 54.2% of
B220+ cells) were allowed to transmigrate for 3 h. The number of mi-
grated cells was counted by FACScan (Becton Dickinson) using a pre-
determined number of 6-lm beads (Polyscience) as an internal
standard [10,24]. The population of transmigrated lymphocytes was
analyzed by ﬂow cytometry.Fig. 1. Colocalization of nepmucin and CD31 in peripheral lymph
node (LN) high endothelial venules (HEVs). Frozen sections of
peripheral LNs were incubated with anti-nepmucin (A) or anti-CD31
mAb (B). (C) is the merged image. Bar, 50 lm. Immunoelectron2.8. Lymphocyte binding assay
Lymphocyte binding to ECs was assayed as previously described
[25].
microscopy showed nepmucin (D, E, and G) and CD31 (F and H)
colocalized at the lateral surface of HEVs, where the ECs formed loose
connections (arrows in E and F) and in vesicle-like structures just
below the plasma membrane of the junctional surface (arrows in G and
H). Bars in (E–H), 300 nm.2.9. Nepmucin-Fc binding assay
Binding of nepmucin-Fc to lymphocytes was detected by FACS
analysis as described previously [26].2.10. Statistical analysis
Students t-test was applied to determine the statistical diﬀerence be-
tween two groups.3. Results
3.1. Nepmucin localizes to intercellular contacts and vesicle-like
structures of vascular endothelial cells
We compared the localization of nepmucin and a pan-endo-
thelial cell marker, CD31, in HEVs of peripheral LNs. Nepmu-
cin was strongly expressed in the lumen and colocalized with
CD31 at the intercellular junctions of HEV ECs (Fig. 1
A–C). Immunoelectron microscopy showed that, within the
junction, both nepmucin (Fig. 1D and E) and CD31 (Fig.
1F) accumulated between loosely connected ECs, and in vesi-
cle-like structures along the intercellular border (Fig. 1G and
3020 S. Jin et al. / FEBS Letters 582 (2008) 3018–3024H). Thus, nepmucin and CD31 are expressed at similar loca-
tions in ECs.
3.2. Nepmucin constitutively undergoes intracellular recycling
from the vesicular structures to the cell surface
Since CD31 is recycled constitutively [15], we asked whether
nepmucin also undergoes recycling. We used MBEC4 cells0 30
Nepmucin
JAM-A
VCAM-1
Fig. 2. Recycling of nepmucin from the intracellular compartment to the cel
endothelial cell 4 (FL-MBEC4) was analyzed and compared to JAM-A and
Fluor 488-conjugated secondary antibody at various times. Bar, 50 lm.
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Fig. 3. Homophilic interaction of nepmucin via its Ig domain. L cells transfe
vector alone (Mock-L) were evaluated for aggregation. (A) A single-cell sus
times. The number of aggregates was counted in 10 microscopic ﬁelds. (B) Up
Lower: FL-L was mixed with an equal number of CFSE-labeled Mock-L and
(C) FL-L or Mock-L was rotated for 60 min with or without 2 mM CaCl2. (D
cells were rotated for 45 min. Data represent the means ± SD of triplicate dexpressing FL-nepmucin (FL-MBEC4) and compared the
behavior of nepmucin to that of JAM-A and VCAM-1, which
are endogenously expressed in MBEC4. Nepmucin reappeared
on the cell surface by 30 min after its complete internalization,
whereas JAM-A and VCAM-1 reappeared at a slower rate
(Fig. 2). At 75 min, nepmucin was found on the cell surface
and within the cytoplasm, indicating that the nepmucin that60 75 min
l border. Intracellular recycling of nepmucin in full-length mouse brain
VCAM-1. The recycling adhesion molecules were detected by Alexa
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nalized. In contrast, JAM-A was found mainly on the cell sur-
face. These results suggest that nepmucin undergoes recycling
at a much faster rate than JAM-A or VCAM-1.A
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Nepmucin JAM-A Merged3.3. Nepmucin mediates homotypic cell adhesion via a site in the
Ig domain diﬀerent from that used for heterophilic binding
We showed previously that nepmucin binds to unidentiﬁed
non-nepmucin molecule(s) on lymphocytes via its Ig domain
[17]. Because nepmucin was expressed at interendothelial con-
tacts and carries an Ig domain, like CD31, we speculated that
nepmucin might also engage in Ca2+-dependent homophilic
adhesion via its Ig domain. To test this, we used a cell aggre-
gation assay. L cells stably expressing FL-nepmucin (FL-L)
or Dmucin-nepmucin (Dmucin-L) formed aggregates in rota-
tion culture, but L cells transfected with vector alone (Mock-
L) did not (Fig. 3A and B). Because FL-L bound to FL-L
but not to Mock-L (Fig. 3B, lower panel), this aggregation
was judged to be mediated by the homophilic adhesion of nep-
mucin. This cell adhesion was Ca2+-dependent (Fig. 3C). In
antibody inhibition experiments using anti-nepmucin mAbs
that recognize the Ig domain, ZAQ1 and ZAQ2 inhibited the
homophilic aggregation, whereas ZAQ3, 4, and 5, and control
rat IgG did not (Fig. 3D). This contrasts with our previous
observation of nepmucin-dependent heterophilic binding, in
which ZAQ3 and ZAQ4, but not ZAQ1 or ZAQ2, inhibited
the adhesion [17]. These results indicate that nepmucin inter-
acts homophilically using a site diﬀerent from that used for
heterophilic adhesion and that both sites are within the Ig do-
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Fig. 4. Lymphocyte transendothelial migration (TEM) across nepmu-
cin-expressing mouse brain endothelial cell 4 (MBEC4) cells. (A)
Expression of nepmucin and JAM-A on FL-MBEC4. Bar, 20 lm. (B)
Mouse lymphocytes were added to IL-1b-treated endothelial cell (EC)
monolayer, and the number of transmigrated cells was counted by ﬂow
cytometry. (C) IL-1b-stimulated EC monolayer was incubated with
ZAQ1 and ZAQ2 to block nepmucins homophilic binding, ZAQ3,
ZAQ4, and ZAQ5 to block heterophilic binding, or control rat IgG.
(D) IL-1b-stimulated EC monolayer was incubated with blocking
mAbs or control rat IgG, and the bound lymphocytes were solubilized
and quantiﬁed by a ﬂuorescence plate reader. Data represent the
means ± SD of triplicate determinations. (B–D) *P < 0.01, **P < 0.005,
and ***P < 0.001.3.4. Nepmucin-expressing ECs may promote lymphocyte TEM
using two distinct adhesion pathways
We next examined whether nepmucin mediates lymphocyte
TEM. We used FL-MBEC4, which lacks CD31 but expresses
nepmucin and JAM-A at intercellular junctions (Fig. 4A). Un-
der IL-1b stimulation, lymphocytes underwent TEM through
an FL-MBEC4 monolayer about three times more eﬃciently
than through Mock-MBEC4 (Fig. 4B), although there was
no apparent diﬀerence in the cell-surface expression of nepmu-
cin and JAM-A in FL-MBEC4 after IL-1b stimulation (data
not shown). Lymphocyte TEM across Dmucin-MBEC4 tended
to increase, although no statistical signiﬁcance was obtained,
indicating that the mucin-like domain plays a relatively minor
role in TEM. Lymphocytes migrated across DIg-MBEC4
poorly, consistent with the nepmucins Ig domain being critical
for lymphocyte TEM. We also examined lymphocyte adhesion
to and TEM across FL-MBEC4 under ﬂow conditions. Since
MBEC4 cells do not express L-selectin ligands, they do not
support L-selectin-dependent lymphocyte rolling. We therefore
used low shear stress conditions (0.025 dyne/cm2) that allowed
L-selectin-independent lymphocyte rolling to analyze the func-
tion of nepmucin in the lymphocyte adhesion/transmigration
cascade. Under these conditions, lymphocytes bound to FL-
MBEC4 at higher levels than to Mock-MBEC4 in vitro (Fig.
S1A). When lymphocytes were allowed to ﬂow under the shear
stress of 0.1 dyne/cm2 for 1 h, approximately 60% of the bound
lymphocytes to FL-MBEC4 transmigrated across them,
whereas only 20% of the bound lymphocytes to Mock-MBEC4
migrated underneath them (Fig. S1B), in compatible with the
hypothesis that nepmucin regulates lymphocyte adhesion toand transmigration across endothelial cells under ﬂow condi-
tions.
We next performed inhibition experiments using the anti-
nepmucin mAbs that selectively block homophilic or hetero-
philic adhesion. Lymphocyte TEM was inhibited when the as-
say was performed with mAb cocktails that blocked
homophilic (ZAQ1 + ZAQ2) or heterophilic (ZAQ3 +
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Fig. 5. Phenotype of nepmucin-binding lymphocytes and of transmigrating lymphocytes across full-length mouse brain endothelial cell 4 (FL-
MBEC4). (A) Nepmucin binding to lymphocytes. Soluble nepmucin (FL-Fc, Dmucin-Fc, or DIg-Fc) or control human IgG was pre-incubated with
PE-conjugated anti-human IgG, and then added to spleen cells. Cells that bound nepmucin were analyzed by ﬂow cytometry. (B) Before and after
transendothelial migration (TEM) assay, lymphocytes were incubated with antibodies against CD4, CD8, and B220, and analyzed by ﬂow cytometry.
(C) Endothelial cell (EC) monolayer was incubated with cocktails of anti-nepmucin mAbs that block homophilic binding or control rat IgG, before
addition of lymphocytes.
3022 S. Jin et al. / FEBS Letters 582 (2008) 3018–3024ZAQ4 + ZAQ5) adhesion (Fig. 4C). A mixture of the two
groups of mAbs was also inhibitory to a comparable extent,
but control IgG showed no inhibition. Neither of the anti-nep-
mucin mAb cocktails aﬀected lymphocyte TEM across Mock-
MBEC4 (data not shown), indicating that the antibody eﬀect
was speciﬁc.
These results indicate that nepmucin promotes lymphocyte
TEM using two distinct adhesion pathways. However, because
lymphocyte adhesion to ECs is a prerequisite for lymphocyte
TEM, blocking adhesion necessarily blocks TEM. We thus
examined whether the inhibitory eﬀect of anti-nepmucin mAbs
on lymphocyte TEM was due to the inhibition of lymphocyte
adhesion. Lymphocyte binding to FL-MBEC4 was inhibited
by the anti-nepmucin mAbs that block heterophilic but not
homophilic binding (Fig. 4D), supporting a role for nepmu-
cins homophilic interactions in lymphocyte TEM. In addition,
lymphocyte binding was also partially inhibited by anti-
VCAM-1 mAb (Fig. 4D). Neither ICAM-1 nor ICAM-2 was
detected in MBEC4 cells. These results suggest that lympho-
cyte binding to FL-MBEC4 is mediated by both nepmucin
and VCAM-1.
To address lymphocyte populations that bind to nepmucin,
we performed FACS analysis using nepmucin-Fc chimeric pro-
teins. As shown in Fig. 5A, substantial proportions of CD4+
and CD8+ T cells and most B cells bound FL-Fc and
Dmucin-Fc, but not DIg-Fc. The level of FL-Fc and Dmucin-
Fc binding was highest in B cells, intermediate in CD4+ T cells
and modest in CD8+ T cells. These results indicate that nep-
mucin binds to lymphocytes via the Ig domain and that large
fractions of lymphocytes express a ligand(s) for nepmucin. A
more detailed study is underway to characterize the cellsexpressing nepmucin ligand(s). We next examined lymphocyte
populations that had transmigrated across FL-MBEC4 cells.
As shown in Fig. 5B, CD4+T, CD8+T, and B cells all showed
TEM, which was almost completely abrogated by cocktails of
anti-nepmucin mAbs. No particular preference appeared to be
present on any cell subsets with regard to their ability to trans-
migrate underneath FL-MBEC4 (Fig. 5C).
Collectively, our ﬁndings indicate that nepmucin uses both
heterophilic and homophilic adhesion pathways to promote
lymphocyte TEM, of which the heterophilic interactions may
be primarily involved in lymphocyte adhesion.4. Discussion
Here, we report that an Ig domain-containing endothelial
adhesion molecule, nepmucin, undergoes rapid intracellular
recycling and regulates lymphocyte TEM. We propose that
nepmucin promotes lymphocyte TEM by acting in two dis-
tinct steps of cell migration. First, lymphocytes bind to the
apical surface of the EC monolayer via the interaction of
nepmucin on ECs with an unidentiﬁed nepmucin ligand(s)
on lymphocytes. Second, nepmucin promotes lymphocyte
transmigration through ECs. The blockage of lymphocyte
TEM by heterophilic adhesion blocking anti-nepmucin mAbs
can be interpreted in two ways: either nepmucin is involved
in lymphocyte–EC adhesion required for TEM or nepmucins
heterophilic interaction is required during lymphocyte TEM.
These ideas are not necessarily mutually exclusive, and nep-
mucins heterophilic interaction may be involved in both
steps. Detailed imaging analysis may help resolve this issue.
S. Jin et al. / FEBS Letters 582 (2008) 3018–3024 3023The observation that anti-nepmucin mAbs, ZAQ1 and
ZAQ2, inhibited lymphocyte TEM without compromising
lymphocyte binding indicates that nepmucins homophilic
interaction is required for lymphocyte TEM. Mamdouh et
al. [15,16] showed that CD31 resides at the LBRC and is
constitutively recycled from LBRC to the EC border; the
recycling CD31-bearing membrane is targeted rapidly to the
site of TEM, which is inhibited by blocking the homophilic
interaction of CD31. Our observations that nepmucin was
present in the vesicular compartment along the intercellular
border and underwent rapid intracellular recycling are consis-
tent with the hypothesis that the rapid and continuous
recycling of nepmucin plays a role in lymphocyte TEM.
Whether the recycling nepmucin is targeted to the region of
the junction where TEM is occurring is currently under
investigation.
Although multiple adhesion molecules are involved in the
TEM of neutrophils and monocytes, the molecular mecha-
nisms regulating lymphocyte TEM are less well understood.
Several adhesion molecules, including ICAM-1, ICAM-2
[27], CD99 [9], JAM-A [11], JAM-C [14], and ALCAM [7],
have been suggested to facilitate lymphocyte TEM. However,
CD31 disruption in mice caused no change in short-term lym-
phocyte traﬃcking or hypersensitivity ear swelling [28], sug-
gesting CD31 plays only a minor role in lymphocyte TEM
or that multiple molecules are redundantly involved in this
process. The present study raises the possibility that nepmucin
regulates lymphocyte TEM independently or in concert with
other molecules. We are now examining the in vivo signiﬁcance
of nepmucin in lymphocyte TEM.
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